Susceptibility of Human T Cell Leukemia Virus Type 1 to Reverse-Transcriptase Inhibitors: Evidence for Resistance to Lamivudine

Nucleoside reverse-transcriptase (RT) inhibitors (NRTIs), including lamivudine (3TC) and zidovudine (Zdv), are being evaluated for the treatment of human T cell lymphotropic virus type 1 (HTLV-1)–associated disease. However, information on the susceptibility of HTLV-1 to these drugs is limited. The...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2001-08, Vol.184 (4), p.507-510
Main Authors: García-Lerma, J. Gerardo, Nidtha, Soumya, Heneine, Walid
Format: Article
Language:English
Subjects:
AIDS
Amino Acid Sequence
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antivirals
Biological and medical sciences
Concise Comunications
Deltaretrovirus Infections - virology
didanosine
Drug Resistance, Microbial
HIV 1
HIV Infections - virology
HIV Reverse Transcriptase - drug effects
HIV Reverse Transcriptase - genetics
HIV-1 - drug effects
HIV-1 - enzymology
Human immunodeficiency virus 1
Human T lymphotropic virus 1
Human T-lymphotropic virus 1 - drug effects
Human T-lymphotropic virus 1 - enzymology
Human viral diseases
Humans
Infectious diseases
Inhibitory concentration 50
Lamivudine - pharmacology
Medical sciences
Microbial Sensitivity Tests - methods
Molecular Sequence Data
Nervous system diseases
Nucleosides
Pharmacology. Drug treatments
Retroviridae
Reverse Transcriptase Inhibitors - pharmacology
RNA-Directed DNA Polymerase - chemistry
RNA-Directed DNA Polymerase - genetics
RNA-Directed DNA Polymerase - metabolism
stavudine
T lymphocytes
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viruses
zalcitabine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nucleoside reverse-transcriptase (RT) inhibitors (NRTIs), including lamivudine (3TC) and zidovudine (Zdv), are being evaluated for the treatment of human T cell lymphotropic virus type 1 (HTLV-1)–associated disease. However, information on the susceptibility of HTLV-1 to these drugs is limited. The activity of 5 NRTIs on HTLV-1 RT was evaluated. IC50 values for Zdv, zalcitabine (ddC), didanosine (ddI), 3TC, and stavudine (d4T) were determined, using an enzymatic assay, for 5 HTLV-1 isolates and for reference wild-type and NRTI-resistant human immunodeficiency virus type 1 (HIV-1). Both HTLV-1 and wild-type HIV-1 were equally susceptible to Zdv, ddC, ddI, and d4T. In contrast, high-level resistance to 3TC was found in all HTLV-1 isolates. The findings support the clinical use of Zdv, ddC, ddI, and d4T but not of 3TC for the antiretroviral treatment of HTLV-1–associated disease
ISSN:0022-1899
1537-6613
DOI:10.1086/322785